Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hiroko Honna is active.

Publication


Featured researches published by Hiroko Honna.


Blood | 2010

Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19)

Kinuko Hirose; Takeshi Inukai; Jiro Kikuchi; Yusuke Furukawa; Tomokatsu Ikawa; Hiroshi Kawamoto; S. Helen Oram; Berthold Göttgens; Nobutaka Kiyokawa; Yoshitaka Miyagawa; Hajime Okita; Koshi Akahane; Xiaochun Zhang; Itaru Kuroda; Hiroko Honna; Keiko Kagami; Kumiko Goi; Hidemitsu Kurosawa; A. Thomas Look; Hirotaka Matsui; Toshiya Inaba; Kanji Sugita

LMO2, a critical transcription regulator of hematopoiesis, is involved in human T-cell leukemia. The binding site of proline and acidic amino acid-rich protein (PAR) transcription factors in the promoter of the LMO2 gene plays a central role in hematopoietic-specific expression. E2A-HLF fusion derived from t(17;19) in B-precursor acute lymphoblastic leukemia (ALL) has the transactivation domain of E2A and the basic region/leucine zipper domain of HLF, which is a PAR transcription factor, raising the possibility that E2A-HLF aberrantly induces LMO2 expression. We here demonstrate that cell lines and a primary sample of t(17;19)-ALL expressed LMO2 at significantly higher levels than other B-precursor ALLs did. Transfection of E2A-HLF into a non-t(17;19) B-precursor ALL cell line induced LMO2 gene expression that was dependent on the DNA-binding and transactivation activities of E2A-HLF. The PAR site in the LMO2 gene promoter was critical for E2A-HLF-induced LMO2 expression. Gene silencing of LMO2 in a t(17;19)-ALL cell line by short hairpin RNA induced apoptotic cell death. These observations indicated that E2A-HLF promotes cell survival of t(17;19)-ALL cells by aberrantly up-regulating LMO2 expression. LMO2 could be a target for a new therapeutic modality for extremely chemo-resistant t(17;19)-ALL.


Leukemia | 2006

Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity

Takeshi Inukai; Xiaochun Zhang; M Goto; Kinuko Hirose; Uno K; Koshi Akahane; Atsushi Nemoto; Kumiko Goi; Hiroki Sato; Kazuhisa Takahashi; Hiroko Honna; Keiko Kagami; K Nakamoto; Hideo Yagita; Ko Okumura; T Koyama-Okazaki; Shinpei Nakazawa; Kanji Sugita

Malignant cells generally acquire some immune escape mechanisms for clonal expansion. Immune escape mechanisms also contribute to the failure of graft-versus-leukemia (GVL) effect after allogeneic hematopoietic stem cell transplantation (allo-SCT). Infant leukemias with mixed-lineage leukemia (MLL) rearrangement have a remarkably short latency, and GVL effect after allo-SCT has not been clearly evidenced in these leukemias. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)- and FasL-mediated cytotoxic pathways play important roles in cytotoxic T-lymphocyte- and natural killer cell-mediated antitumor immunity and optimal GVL activity. We investigated the in vitro sensitivity of MLL-rearranged acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML) cells to TRAIL- and FasL-mediated cytotoxicity. Most of cell lines and primary leukemia cells were highly resistant to TRAIL primarily owing to low cell-surface expression of death receptors in ALL and simultaneous expression of decoy receptors in AML. Nearly half of cell lines and majority of primary leukemia cells showed low sensitivity to FasL. These results suggest that resistance to death-inducing ligands, particularly to TRAIL, could be one of the mechanisms for a rapid clonal expansion and a poor sensitivity to the GVL effect in infant leukemias with MLL rearrangement.


Cancer Research | 2007

Fms-like Tyrosine Kinase 3 Ligand Stimulation Induces MLL-Rearranged Leukemia Cells into Quiescence Resistant to Antileukemic Agents

Yoshiyuki Furuichi; Kumiko Goi; Takeshi Inukai; Hiroki Sato; Atsushi Nemoto; Kazuya Takahashi; Koshi Akahane; Kinuko Hirose; Hiroko Honna; Itaru Kuroda; Xiaochun Zhang; Keiko Kagami; Yasuhide Hayashi; Kenichi Harigaya; Shinpei Nakazawa; Kanji Sugita

Fms-like tyrosine kinase 3 (FLT3) is highly expressed in acute lymphoblastic leukemia with the mixed-lineage leukemia (MLL) gene rearrangement refractory to chemotherapy. We examined the biological effect of FLT3-ligand (FL) on 18 B-precursor leukemic cell lines with variable karyotypic abnormalities, and found that nine of nine MLL-rearranged cell lines with wild-type FLT3, in contrast to other leukemic cell lines, are significantly inhibited in their proliferation in a dose-dependent manner by FL. This inhibition was due to induction of the G0-G1 arrest. A marked up-regulation of p27 by suppression of its protein degradation and an abrogation of constitutive signal transducers and activators of transcription 5 phosphorylation were revealed in arrested leukemia cells after FL stimulation. Importantly, FL treatment rendered not only cell lines but also primary leukemia cells with MLL rearrangement resistant to chemotherapeutic agents. MLL-rearranged leukemia cells adhering to the bone marrow stromal cell line, which expresses FL as the membrane-bound form, were induced to quiescent state resistant to chemotherapeutic agents, but their chemosensitivity was significantly restored in the presence of neutralizing anti-FL antibody. The FL/FLT3 interaction between leukemia cells and bone marrow stromal cells expressing FL at high levels should contribute, at least in part, to persistent minimal-residual disease of MLL-rearranged leukemia in bone marrow.


Bone Marrow Transplantation | 2011

Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN

Kumiko Goi; Takeshi Inukai; Hiroko Honna; Koshi Akahane; Kinuko Hirose; Itaru Kuroda; N Hasuda; K Koshizuka; K Takano; Kanji Sugita

Although autologous tandem hematopoietic SCT has improved the prognosis of patients with advanced high-risk neuroblastoma, the results remain unsatisfactory. In an attempt to induce the graft-versus-tumor effect, we performed autologous PBSCT followed by allogeneic cord blood transplantation in three consecutive advanced neuroblastoma cases with marked BM infiltration and high MYCN amplification. Severe acute complications did not occur in any patient and they have maintained disease-free survival for 37–60 months. This strategy appears to be feasible and effective for the treatment of extremely high-risk neuroblastoma cases.


British Journal of Haematology | 2006

Natural pregnancy and delivery after allogeneic bone marrow transplantation in a Fanconi anaemia patient

Kumiko Goi; Kanji Sugita; Makoto Nakamura; Takeshi Inukai; Hiroko Honna; Kinuko Hirose; Itaru Kuroda; Kazuhiko Hoshi; Shinpei Nakazawa

Mohamad Mohty Jean El-Cheikh Philippe A. Cassier Catherine Faucher Sabine Fürst Norbert Vey Anne-Marie Stoppa Daniele Sainty Christine Arnoulet Luc Xerri Jean-Albert Gastaut Didier Blaise Reda Bouabdallah Unité de Transplantation et de Thérapie Cellulaire (UTTC), Institut Paoli-Calmettes, Département d’Hématologie, Institut Paoli-Calmettes, Département de Biopathologie, Institut Paoli-Calmettes, Université de la Méditerranée, Faculté de Médecine, and INSERM, UMR 599, Marseille, France. E-mail: [email protected]


Leukemia Research | 2011

Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosis.

Xiaochun Zhang; Takeshi Inukai; Koshi Akahane; Kinuko Hirose; Itaru Kuroda; Hiroko Honna; Kumiko Goi; Keiko Kagami; Tetsuzo Tauchi; Hideo Yagita; Kanji Sugita

Philadelphia-chromosome (Ph1)-positive leukemia cells frequently express death receptors DR4/DR5 for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and show high TRAIL-sensitivity. It has been reported that imatinib damaged cardiomyocytes by triggering endoplasmic reticulum (ER) stress and that ER stress inducers intensified TRAIL-sensitivity of some cancer cells by upregulating DR4/DR5 expression. In fact, ER stress inducers enhanced TRAIL-sensitivity of Ph1-positive leukemia cells by upregulating DR4/DR5 expression. In contrast, imatinib did not induce ER stress responses and unexpectedly downregulated DR4/DR5 expression, indicating that sensitization of Ph1-positive leukemia cells to TRAIL-mediated cellular immunity by imatinib through upregulation of DR4/DR5 expression is unlikely.


Leukemia | 2010

Specific induction of CD33 expression by E2A–HLF: the first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor

Koshi Akahane; Takeshi Inukai; Toshiya Inaba; Hidemitsu Kurosawa; A T Look; Nobutaka Kiyokawa; Junichiro Fujimoto; Hiroaki Goto; Mikiya Endo; Xiaochun Zhang; Kinuko Hirose; Itaru Kuroda; Hiroko Honna; Keiko Kagami; Kumiko Goi; Shinpei Nakazawa; Kanji Sugita

Specific induction of CD33 expression by E2A–HLF: the first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor


British Journal of Haematology | 2007

Monitoring neutrophil engraftment in allogeneic stem cell transplantation by flow cytometric analysis of neutrophil‐specific antigens NA1 and NA2

Takeshi Inukai; Kanako Uno; Kikuyo Taniguchi; Kumiko Goi; Toru Tezuka; Atsushi Nemoto; Kazuya Takahashi; Hiroki Sato; Koshi Akahane; Kinuko Hirose; Hiroko Honna; Keiko Kagami; Asako Hiraoka; Misae Tanihiro; Shinpei Nakazawa; Kanji Sugita

Neutrophil‐specific antigen (NA) expression on neutrophils was analysed in 18 Japanese children before and after allogeneic stem cell transplantation (allo‐SCT) with myeloablative regimen. Donor–recipient NA‐incompatibility was present in one of eight NA1/NA2 heterozygous patients and eight of 10 NA1/NA1 or NA2/NA2 homozygous patients. After allo‐SCTs from NA‐incompatible donors, a neutrophil recipient‐to‐donor conversion was confirmed in all cases. Conversion to donor NA type was complete before the absolute neutrophil count reached 0·1 × 109/l. These observations indicate that flow cytometric analysis of NA antigens is a simple and useful method for monitoring neutrophil engraftment in NA‐incompatible allo‐SCT.


Bone Marrow Transplantation | 2009

Little impact of donor/recipient major mismatch for neutrophil-specific antigen NA2 on neutrophil recovery after allogeneic SCT.

Takeshi Inukai; Kumiko Goi; Toru Tezuka; Kanako Uno; A Nemoto; K Takahashi; Hiroki Sato; Koshi Akahane; Kinuko Hirose; Hiroko Honna; Itaru Kuroda; K Kagami; K Nakamoto; K Taniguchi; Shinpei Nakazawa; Kanji Sugita

The Fcγ receptor IIIb (FcγRIIIb), a receptor for the Fcγ region of IgG, is specifically expressed on neutrophils. It has two allelic polymorphisms, NA1 and NA2, which are highly immunogenic and act as targets in alloimmune or autoimmune neutropenia. Thus, neutrophil antigens (NA) compatibility of donor/recipient pairs might be expected to affect the engraftment of neutrophils after allogeneic SCT (allo-SCT). Here, the impact of NA compatibility of 17 patients and their donors undergoing allo-SCT with a myeloablative regimen was determined. Leukocyte depletion filters were used for all transfusions before and post-SCT; most patients received G-CSF after transplant. Major mismatches for NA1 and NA2 were present in 1 and 7 patient/donor pairs, respectively. These eight patients receiving NA major-mismatched allo-SCT were compared with nine patients who received NA compatible allo-SCT. Engraftment of neutrophils and the incidence of post-engraftment neutropenia were found to be identical in the two groups. Despite the limitations in statistical power because of the small number of patients analyzed, these observations suggest that the major mismatching for NA2 antigen has little impact on the engraftment of neutrophils after myeloablative allo-SCT, at least in patients transfused using leukocyte depletion filters and receiving G-CSF after transplantation.


Histopathology | 2007

Revision of the cytological diagnosis of CNS relapse into aseptic meningitis in a patient with TEL-AML1+ acute lymphoblastic leukaemia by FISH analysis of mononuclear cells in cerebrospinal fluid.

Takeshi Inukai; Koshi Akahane; Atsushi Nemoto; Itaru Kuroda; S Noguchi; Kinuko Hirose; Hiroko Honna; Kumiko Goi; Tetsuo Kondo; S Iwasa; Shin-ichi Murata; R Kato; Shinpei Nakazawa; Kanji Sugita

vesicles. Based on our results, the name Paneth cell-like metaplasia should be discarded, given that there are no immunohistochemical similarities between these granules, and true metaplasia does not occur. In our series, no clinical suspicion of sperm path obstruction existed, indicating that the presence of these changes cannot be used as a diagnostic marker of obstruction. The extensive necrosis that accompanies testicular tumours produces a massive release of substances for which the endocytic machinery of epididymis epithelial cells is not prepared. This excessive endocytosis probably leads to the accumulation of an increased number of secondary lysosomes in the cytoplasm. In conclusion, granular changes in epididymal epithelial cells represent an accumulation of lysosomes. This accumulation is probably caused by increased endocytic activity secondary to excessive fluid, which might be due not only to obstruction of the spermatic path but also to massive fluid release by a testicular tumour.

Collaboration


Dive into the Hiroko Honna's collaboration.

Top Co-Authors

Avatar

Kanji Sugita

University of Yamanashi

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kumiko Goi

University of Yamanashi

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Itaru Kuroda

University of Yamanashi

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Keiko Kagami

University of Yamanashi

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge